DE EN
  • Array

    About us

HypoPet AG was founded as a spin-off company from the University of Zürich in 2013 by Patrik Paulus, Gabriela Senti, Thomas Kündig and Martin Bachmann. Subsequently it was awarded the prestigious Swiss Technology Award for its paradigm shifting concept of neutralizing the major cat allergen known to cause allergy and asthma in humans by simple vaccination of the cat with its HypoCat vaccine. In 2014 HypoPet received a R&D project grant from the Swiss Commission for Technology and Innovation to advance the HypoCat vaccine project and later that year entered into a Commercialization, manufacture, and distribution agreement with Benchmark Holdings PLC. In May 2017 HypoPet AG and Saiba Animal Health GmbH merged into today's HypoPet AG with its extended drug pipeline.